GAITHERSBURG, Md. (WJZ) — Maryland-based Novavax announced Thursday its COVID-19 vaccine was 89.3% effective in a Phase 3 trial in the United Kingdom.
The study was conducted in partnership with the U.K. Government’s Vaccines Taskforce. Novavax also announced successful results of its Phase 2B study conducted in South Africa.READ MORE: COVID-19 In Maryland: 932 New Cases Reported, 11 More Deaths
- TIMELINE: Coronavirus In Maryland, Tracking The Spread
- Latest coronavirus stories from WJZ
- Latest CDC Guidelines
In a statement, Novavax’s president and CEO Stanley Erck said:READ MORE: 'An Incredible Therapy' | Hagerstown Doctor Says Monoclonal Antibody Treatment Provides Fast Recoveries For Some COVID Patients
“With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants. In addition, our PREVENT-19 US and Mexico clinical trial has randomized over 16,000 participants toward our enrollment goal of 30,000. NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants.”
Novavax’s COVID-19 vaccine contains a full-length, prefusion spike protein made using Novavax’s recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M adjuvant.
The purified protein is encoded by the genetic sequence of the SARS-CoV-2 spike (S) protein and is produced in insect cells. It can neither cause COVID-19 nor can it replicate, is stable at 2°C to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.MORE NEWS: Rockville Police Officer, Maryland National Guardsman Daniel Morozewicz Arrested On Child Porn Charge